The following represents disclosure information provided by authors of this abstract. The program committee has reviewed all presenting author disclosure reports, identified potential conflicts of interest, and implemented strategies to manage those areas of conflict, where appropriate. All relationships are considered compensated. Relationships are self-held unless otherwise noted. I = Immediate Family Member, Inst = My Institution
 
Open Payments is a public database containing information reported by companies about payments made to US-licensed physicians (Open Payments)
Final results of a phase I/II dose-escalation study of fractionated dose 177Lu-PSMA-617 for progressive metastatic castration resistant prostate cancer (mCRPC).
 
Scott T. Tagawa
Stock and Other Ownership Interests - Convergent Therapeutics
Consulting or Advisory Role - 4D Pharma; Abbvie; AIkido Pharma; Ambrx; Amgen; Astellas Pharma; Bayer; Bicycle Therapeutics; Blue Earth Diagnostics; Boston Scientific; Clarity Pharmaceuticals; Clovis Oncology; Convergent Therapeutics; Daiichi Sankyo; Dendreon; Endocyte; Exelixis; Genentech; Genomic Health; Gilead Sciences; Hookipa Pharma; Immunomedics; Janssen; Karyopharm Therapeutics; Medivation; Merck; Myovant Sciences; Novartis; Pfizer; POINT Biopharma; QED Therapeutics; Regeneron; Sanofi; Seagen; Telix Pharmaceuticals; Tolmar; TransThera Biosciences
Research Funding - Abbvie (Inst); Ambrx (Inst); Amgen (Inst); Astellas Pharma (Inst); AstraZeneca (Inst); AVEO (Inst); Bayer (Inst); Boehringer Ingelheim (Inst); Bristol-Myers Squibb (Inst); Clarity Pharmaceuticals (Inst); Clovis Oncology (Inst); Dendreon (Inst); Endocyte (Inst); Exelixis (Inst); Genentech (Inst); Immunomedics (Inst); Inovio Pharmaceuticals (Inst); Janssen (Inst); Karyopharm Therapeutics (Inst); Lilly (Inst); Medivation (Inst); Merck (Inst); Millennium (Inst); Newlink Genetics (Inst); Novartis (Inst); POINT Biopharma (Inst); Progenics (Inst); Rexahn Pharmaceuticals (Inst); Sanofi (Inst); Stem CentRx (Inst)
Patents, Royalties, Other Intellectual Property - Patent Royalty from Immunomedics / Gilead
Travel, Accommodations, Expenses - Amgen; Astellas Pharma; Immunomedics; Merck; Sanofi
(OPTIONAL) Uncompensated Relationships - ATLAB Pharma; Phosplatin Therapeutics
 
Charlene Thomas
Travel, Accommodations, Expenses - Inovio Pharmaceuticals; Nektar; Pfizer
 
Jones T. Nauseef
Employment - Convergent Therapeutics
Honoraria - Pfizer
Consulting or Advisory Role - AIQ Solutions; Bayer; Pfizer
Travel, Accommodations, Expenses - Digital Science Press; Pfizer
 
A. Oliver Sartor
Stock and Other Ownership Interests - Abbott Laboratories; Abbvie; Cardinal Health; Clarity Pharmaceuticals; Convergent Therapeutics; Fusion Pharmaceuticals; Lilly; POINT Biopharma; PSMA Therapeutics; Ratiopharm; Telix Pharmaceuticals; United Health Group
Honoraria - Intellisphere; Lantheus Medical Imaging; Novartis
Consulting or Advisory Role - Advanced Accelerator Applications; Amgen; ARTbio; Astellas Pharma; AstraZeneca; Bavarian Nordic; Bayer; Blue Earth Diagnostics; Bristol-Myers Squibb; Clarity Pharmaceuticals; Clovis Oncology; Constellation Pharmaceuticals; Dendreon; EMD Serono; Fusion Pharmaceuticals; Hengrui Therapeutics; Isotopen Technologien; Janssen; MacroGenics; Medscape; Merck; Morphimmune; Myovant Sciences; Myriad Genetics; Noria Therapeutics; Northstar; Novartis; Noxopharm; Pfizer; Point Biopharma; Progenics; Ratio; Sanofi; Telix Pharmaceuticals; TEmpus; TeneoBio; Tessa Therapeutics; Theragnostics
Research Funding - Advanced Accelerator Applications (Inst); Amgen (Inst); AstraZeneca (Inst); Bayer (Inst); Constellation Pharmaceuticals (Inst); Dendreon (Inst); Endocyte (Inst); InVitae (Inst); Janssen; Lantheus Medical Imaging (Inst); Merck (Inst); Progenics; Sanofi (Inst); SOTIO
Patents, Royalties, Other Intellectual Property - Koochekpour, Sartor AO, inventors. Saposin C and receptors as targets for treatment of benign and malignant disorders. US patent awarded January 23, 2007 (patent no. 7,166,691).
Expert Testimony - Sanofi
Travel, Accommodations, Expenses - AstraZeneca; Bayer; Johnson & Johnson; Lantheus Medical Imaging; Progenics; Sanofi
 
Michael Philip Sun
No Relationships to Disclose
 
Sandra Huicochea Castellanos
No Relationships to Disclose
 
Andres Ricaurte Fajardo
No Relationships to Disclose
 
Himisha Beltran
Consulting or Advisory Role - AstraZeneca; Bayer; Daicchi Sankyo; Merck; Novartis; Pfizer; Sanofi
Research Funding - Bristol Myers Squibb Foundation (Inst); Circle Pharma (Inst); Daiichi Sankyo (Inst); Novartis (Inst)
Travel, Accommodations, Expenses - Janssen Oncology
 
Francesca Demichelis
No Relationships to Disclose
 
Michael Sigouros
No Relationships to Disclose
 
Francesco Orlando
No Relationships to Disclose
 
Ana M. Molina
Consulting or Advisory Role - EISAI; Janssen
 
Zachary Davidson
No Relationships to Disclose
 
Amie Patel
No Relationships to Disclose
 
Brian E. Lewis
No Relationships to Disclose
 
David M. Nanus
Consulting or Advisory Role - Telix Pharmaceuticals
 
Shankar Vallabhajosula
Employment - Convergent Therapeutics
Leadership - Convergent Therapeutics
Stock and Other Ownership Interests - Convergent Therapeutics
Consulting or Advisory Role - Convergent Therapeutics
 
Neil Harrison Bander
Leadership - Convergent Therapeutics; XenImmune Therapeutics
Stock and Other Ownership Interests - Convergent Therapeutics; XenImmune Therapeutics
Consulting or Advisory Role - Convergent Therapeutics; XenImmune Therapeutics
Patents, Royalties, Other Intellectual Property - Patents to anti-PSMA antibodies assigned to Cornell Univ; Royalty--Cook Urological
 
Joseph Osborne
Honoraria - Siemens Healthineers
Consulting or Advisory Role - Siemens Healthineers
Travel, Accommodations, Expenses - Siemens Healthineers